

FINANCIAL DISCLOSURE REPORT FOR CALENDAR YEAR 2015

Report Required by the Ethics
in Government Act of 1978
(5 U.S.C. app. §§ 101-111)

1. Person Reporting (last name, first, middle initial) Ray, J. Thomas	2. Court or Organization U. S. District Court - ED AR	3. Date of Report 08/04/2016
4. Title (Article III judges indicate active or senior status; magistrate judges indicate full- or part-time) U. S. Magis. Judge - Full Time	5a. Report Type (check appropriate type) ☐ Nomination ☐ Date ☐ Initial ☒ Annual ☐ Final 5b. ☒ Amended Report	6. Reporting Period 1/1/2015 to 12/31/2015
7. Chambers or Office Address Richard Sheppard Arnold United States Courthouse 500 West Capitol, Room D 144 Little Rock, AR 72201		
IMPORTANT NOTES: The instructions accompanying this form must be followed. Complete all parts, checking the NONE box for each part where you have no reportable information.		

I. POSITIONS. (Reporting individual only; see pp. 9-13 of filing instructions.)

☐ NONE (No reportable positions.)

	<u>POSITION</u>	<u>NAME OF ORGANIZATION/ENTITY</u>
1.	Trustee	Rollover IRA
2.	Trustee	IRA #1
3.	Trustee	Inherited IRA (X)
4.	Trustee	Trust #1
5.	Trustee	Trust #2
6.	Trustee	Trust #3

II. AGREEMENTS. (Reporting individual only; see pp. 14-16 of filing instructions.)

☒ NONE (No reportable agreements.)

	<u>DATE</u>	<u>PARTIES AND TERMS</u>
1.		
2.		
3.		

FINANCIAL DISCLOSURE REPORT

Page 2 of 20

Name of Person Reporting

Ray, J. Thomas

Date of Report

08/04/2016

III. NON-INVESTMENT INCOME. *(Reporting individual and spouse; see pp. 17-24 of filing instructions.)***A. Filer's Non-Investment Income**NONE *(No reportable non-investment income.)*DATESOURCE AND TYPEINCOME
(yours, not spouse's)

1. _____

2. _____

3. _____

4. _____

B. Spouse's Non-Investment Income - *If you were married during any portion of the reporting year, complete this section.**(Dollar amount not required except for honoraria.)*NONE *(No reportable non-investment income.)*DATESOURCE AND TYPE

1. _____

2. _____

3. _____

4. _____

IV. REIMBURSEMENTS *— transportation, lodging, food, entertainment.**(Includes those to spouse and dependent children; see pp. 25-27 of filing instructions.)*NONE *(No reportable reimbursements.)*SOURCEDATESLOCATIONPURPOSEITEMS PAID OR PROVIDED

1. _____

2. _____

3. _____

4. _____

5. _____

FINANCIAL DISCLOSURE REPORT

Page 3 of 20

Name of Person Reporting

Ray, J. Thomas

Date of Report

08/04/2016

V. GIFTS. *(Includes those to spouse and dependent children; see pp. 28-31 of filing instructions.)*NONE *(No reportable gifts.)*

	<u>SOURCE</u>	<u>DESCRIPTION</u>	<u>VALUE</u>
1.			
2.			
3.			
4.			
5.			

VI. LIABILITIES. *(Includes those of spouse and dependent children; see pp. 32-33 of filing instructions.)*NONE *(No reportable liabilities.)*

	<u>CREDITOR</u>	<u>DESCRIPTION</u>	<u>VALUE CODE</u>
1.	FLC	Note and Mortgage on Rental Prop., Pulaski County, AR (Pt. VII, Line 65)	J
2.			
3.			
4.			
5.			

FINANCIAL DISCLOSURE REPORT

Page 4 of 20

Name of Person Reporting

Ray, J. Thomas

Date of Report

08/04/2016

VII. INVESTMENTS and TRUSTS – income, value, transactions (Includes those of spouse and dependent children; see pp. 34-60 of filing instructions.)

☐ NONE (No reportable income, assets, or transactions.)

A. Description of Assets (including trust assets) Place "(X)" after each asset exempt from prior disclosure	B. Income during reporting period		C. Gross value at end of reporting period		D. Transactions during reporting period				
	(1) Amount Code 1 (A-H)	(2) Type (e.g., div., rent, or int.)	(1) Value Code 2 (J-P)	(2) Value Method Code 3 (Q-W)	(1) Type (e.g., buy, sell, redemption)	(2) Date mm/dd/yy	(3) Value Code 2 (J-P)	(4) Gain Code 1 (A-H)	(5) Identity of buyer/seller (if private transaction)
1. Agios C.S.		None	J	T	Buy	12/07/15	J		
2. Alexion C.S.		None	K	T	Buy	05/06/15	K		
3. Arch Coal C.S.	A	Dividend			Sold	02/09/15	J		
4. Bank of America C.S.	A	Dividend	K	T					
5. Barrick Gold C.S.	A	Dividend	K	T	Sold (part)	11/03/15	J		
6. Berkshire Hathaway (B) C.S.		None	M	T					
7. Biogen C.S.		None	L	T	Buy	10/13/15	L		
8. BP PLC ADR	B	Dividend	K	T					
9. Bristol Meyers C.S.	A	Dividend	K	T					
10. Celgene C.S.		None	K	T	Buy	11/13/15	K		
11. Cenovus Energy Inc. C.S.	B	Dividend	K	T					
12. Chevron C.S.	C	Dividend	M	T					
13. Cisco C.S.	A	Dividend	K	T	Sold (part)	02/06/15	K	C	
14. Corning C.S.	B	Dividend	M	T	Sold (part)	01/26/15	L	E	
15. Conoco Phillips C.S.	C	Dividend	M	T					
16. Diamond Offshore Drilling C.S.	A	Dividend			Sold	10/14/15	J		
17. Dow Chemical Co. C.S.	A	Dividend	J	T					

1. Income Gain Codes: (See Columns B1 and D4)	A = \$1,000 or less F = \$50,001 - \$100,000	B = \$1,001 - \$2,500 G = \$100,001 - \$1,000,000	C = \$2,501 - \$5,000 H1 = \$1,000,001 - \$5,000,000	D = \$5,001 - \$15,000 H2 = More than \$5,000,000	E = \$15,001 - \$50,000
2. Value Codes (See Columns C1 and D3)	J = \$15,000 or less N = \$250,001 - \$500,000 P3 = \$25,000,001 - \$50,000,000	K = \$15,001 - \$50,000 O = \$500,001 - \$1,000,000	L = \$50,001 - \$100,000 P1 = \$1,000,001 - \$5,000,000 P4 = More than \$50,000,000	M = \$100,001 - \$250,000 P2 = \$5,000,001 - \$25,000,000	
3. Value Method Codes (See Column C2)	Q = Appraisal U = Book Value	R = Cost (Real Estate Only) V = Other	S = Assessment W = Estimated	T = Cash Market	

FINANCIAL DISCLOSURE REPORT

Page 5 of 20

Name of Person Reporting

Ray, J. Thomas

Date of Report

08/04/2016

VII. INVESTMENTS and TRUSTS -- income, value, transactions (Includes those of spouse and dependent children; see pp. 34-60 of filing instructions.)

☐ NONE (No reportable income, assets, or transactions.)

A. Description of Assets (including trust assets) Place "(X)" after each asset exempt from prior disclosure	B. Income during reporting period		C. Gross value at end of reporting period		D. Transactions during reporting period				
	(1) Amount Code 1 (A-H)	(2) Type (e.g., div., rent, or int.)	(1) Value Code 2 (J-P)	(2) Value Method Code 3 (Q-W)	(1) Type (e.g., buy, sell, redemption)	(2) Date mm/dd/yy	(3) Value Code 2 (J-P)	(4) Gain Code 1 (A-H)	(5) Identity of buyer/seller (if private transaction)
18. Eli Lilly C.S.	D	Dividend	N	T					
19. Encana Corp. C.S.	A	Dividend	K	T					
20. Exelis Inc. C.S.	A	Dividend			Sold	04/21/15	L	E	
21. Exxon Mobil Corp. C.S.	D	Dividend	N	T					
22. Fairfax Financial Hldgs C.S.	C	Dividend	N	T					
23. Freeport McMoran C.S.	A	Dividend	K	T	Sold (part)	11/03/15	J		
24. Gilead, C.S.	A	Dividend	K	T	Buy	02/05/15	K		
25. HP Inc., C.S.	B	Dividend	K	T					
26. Hewlett Packard ENTE, C.S.	A	Dividend	K	T	Spinoff (from line 25)	12/01/15	K		
27. Intel C.S.	B	Dividend	L	T					
28. J P Morgan Chase C.S.	B	Dividend	L	T					
29. Johnson & Johnson C.S.	D	Dividend	N	T					
30. Leucadia Corp. C.S.	A	Dividend			Sold	09/23/15	K		
31. Lexmark Intl Inc. C.S.	A	Dividend	J	T	Sold (part)	01/27/15	K	D	
32. Medivation Inc., C.S.		None	K	T	Buy	07/10/15	K		
33. Merck & Co. Inc. C.S.	D	Dividend	N	T					
34. MFC Industries C.S.	A	Dividend			Sold	11/03/15	J		

1. Income Gain Codes: (See Columns B1 and D4)	A = \$1,000 or less F = \$50,001 - \$100,000	B = \$1,001 - \$2,500 G = \$100,001 - \$1,000,000	C = \$2,501 - \$5,000 H1 = \$1,000,001 - \$5,000,000	D = \$5,001 - \$15,000 H2 = More than \$5,000,000	E = \$15,001 - \$50,000
2. Value Codes (See Columns C1 and D3)	J = \$15,000 or less N = \$250,001 - \$500,000 P3 = \$25,000,001 - \$50,000,000	K = \$15,001 - \$50,000 O = \$500,001 - \$1,000,000	L = \$50,001 - \$100,000 P1 = \$1,000,001 - \$5,000,000 P4 = More than \$50,000,000	M = \$100,001 - \$250,000 P2 = \$5,000,001 - \$25,000,000	
3. Value Method Codes (See Column C2)	Q = Appraisal U = Book Value	R = Cost (Real Estate Only) V = Other	S = Assessment W = Estimated	T = Cash Market	

FINANCIAL DISCLOSURE REPORT

Page 6 of 20

Name of Person Reporting

Ray, J. Thomas

Date of Report

08/04/2016

VII. INVESTMENTS and TRUSTS -- income, value, transactions (Includes those of spouse and dependent children; see pp. 34-60 of filing instructions.)

☐ NONE (No reportable income, assets, or transactions.)

A. Description of Assets (including trust assets) Place "(X)" after each asset exempt from prior disclosure	B. Income during reporting period		C. Gross value at end of reporting period		D. Transactions during reporting period				
	(1) Amount Code 1 (A-H)	(2) Type (e.g., div., rent, or int.)	(1) Value Code 2 (J-P)	(2) Value Method Code 3 (Q-W)	(1) Type (e.g., buy, sell, redemption)	(2) Date mm/dd/yy	(3) Value Code 2 (J-P)	(4) Gain Code 1 (A-H)	(5) Identity of buyer/seller (if private transaction)

35. National Oilwell Varco C.S.	A	Dividend	K	T	Buy	12/15/15	K		
36. Newmont Mining C.S.	A	Dividend	K	T					
37. Nokia C.S.	A	Dividend			Sold	01/26/15	K	E	
38. Peabody Energy Corp. C.S.	A	Dividend	J	T					
39. Permian Basin Trust C.S.	B	Dividend	J	T	Sold (part)	12/21/15	J		
40. Pfizer Inc. C.S.	C	Dividend	L	T					
41. Phillips 66 C.S.	C	Dividend	M	T					
42. Precision Drilling C.S.	A	Dividend	J	T					
43. Rio Tinto ADR	A	Dividend	J	T					
44. Roche ADR	A	Dividend	J	T					
45. Sanofi Aventis C.S.	C	Dividend	L	T					
46. Seacor Holdings C.S.		None	K	T					
47. Stryker Corp. C.S.	A	Dividend	K	T					
48. Teck Resources C.S.	A	Dividend	J	T					
49. Tejon Ranch Co. C.S.		None	J	T					
50. Thompson Creek Metals C.S.		None			Sold	11/03/15	J		
51. Transocean Inc. C.S.	A	Dividend			Sold	11/03/15	J		

1. Income Gain Codes: (See Columns B1 and D4)	A = \$1,000 or less F = \$50,001 - \$100,000	B = \$1,001 - \$2,500 G = \$100,001 - \$1,000,000	C = \$2,501 - \$5,000 H1 = \$1,000,001 - \$5,000,000	D = \$5,001 - \$15,000 H2 = More than \$5,000,000	E = \$15,001 - \$50,000
2. Value Codes (See Columns C1 and D3)	J = \$15,000 or less N = \$250,001 - \$500,000 P3 = \$25,000,001 - \$50,000,000	K = \$15,001 - \$50,000 O = \$500,001 - \$1,000,000	L = \$50,001 - \$100,000 P1 = \$1,000,001 - \$5,000,000 P4 = More than \$50,000,000	M = \$100,001 - \$250,000 P2 = \$5,000,001 - \$25,000,000	
3. Value Method Codes (See Column C2)	Q = Appraisal U = Book Value	R = Cost (Real Estate Only) V = Other	S = Assessment W = Estimated	T = Cash Market	

FINANCIAL DISCLOSURE REPORT

Page 7 of 20

Name of Person Reporting

Ray, J. Thomas

Date of Report

08/04/2016

VII. INVESTMENTS and TRUSTS -- income, value, transactions (Includes those of spouse and dependent children; see pp. 34-60 of filing instructions.)

☐ NONE (No reportable income, assets, or transactions.)

A. Description of Assets (including trust assets) Place "(X)" after each asset exempt from prior disclosure	B. Income during reporting period		C. Gross value at end of reporting period		D. Transactions during reporting period				
	(1) Amount Code 1 (A-H)	(2) Type (e.g., div., rent, or int.)	(1) Value Code 2 (J-P)	(2) Value Method Code 3 (Q-W)	(1) Type (e.g., buy, sell, redemption)	(2) Date mm/dd/yy	(3) Value Code 2 (J-P)	(4) Gain Code 1 (A-H)	(5) Identity of buyer/seller (if private transaction)
52. Tsakos C.S.	B	Dividend	K	T					
53. Vale ADR	A	Dividend	J	T					
54. Valero Energy C.S.	D	Dividend	M	T					
55. Wells Fargo C.S.	B	Dividend	L	T					
56. Weyerhaeuser Co C.S.	A	Dividend	J	T					
57. Fort Smith WTR Bond	B	Interest			Redeemed	10/01/15	K	A	
58. UCA Rev. Bond	B	Interest	L	T					
59. Money Market (Cash Equivalents)	A	Interest	L	T					
60.									
61. ORI/Acadia & Ver. Par., LA; McGowan Inc.; Zachry Exploration	F	Royalty	N	W					
62. ORI/Regan County, TX/Pioneer Natural Resources	A	Royalty	K	W					
63. W/I; Acadia & Vermillion Par., LA; McGowan Inc.	F	Royalty	N	W					
64. ORI/Acadia Par., LA; Zachry Exploraton (X)	E	Royalty	N	W					
65. Rental Property (Pulaski County, AR)	D	Rent	N	W					
66.									
67. Rollover IRA	E	Dividend	P1	T					
68. - Money Market (Cash Equivalents)									

1. Income Gain Codes: (See Columns B1 and D4)	A = \$1,000 or less F = \$50,001 - \$100,000	B = \$1,001 - \$2,500 G = \$100,001 - \$1,000,000	C = \$2,501 - \$5,000 H1 = \$1,000,001 - \$5,000,000	D = \$5,001 - \$15,000 H2 = More than \$5,000,000	E = \$15,001 - \$50,000
2. Value Codes (See Columns C1 and D3)	J = \$15,000 or less N = \$250,001 - \$500,000 P3 = \$25,000,001 - \$50,000,000	K = \$15,001 - \$50,000 O = \$500,001 - \$1,000,000	L = \$50,001 - \$100,000 P1 = \$1,000,001 - \$5,000,000 P4 = More than \$5,000,000	M = \$100,001 - \$250,000 P2 = \$5,000,001 - \$25,000,000	
3. Value Method Codes (See Column C2)	Q = Appraisal U = Book Value	R = Cost (Real Estate Only) V = Other	S = Assessment W = Estimated	T = Cash Market	

FINANCIAL DISCLOSURE REPORT

Page 8 of 20

Name of Person Reporting

Ray, J. Thomas

Date of Report

08/04/2016

VII. INVESTMENTS and TRUSTS -- income, value, transactions (Includes those of spouse and dependent children; see pp. 34-60 of filing instructions.)

☐ NONE (No reportable income, assets, or transactions.)

A. Description of Assets (including trust assets) Place "(X)" after each asset exempt from prior disclosure	B. Income during reporting period		C. Gross value at end of reporting period		D. Transactions during reporting period				
	(1) Amount Code 1 (A-H)	(2) Type (e.g., div., rent, or int.)	(1) Value Code 2 (J-P)	(2) Value Method Code 3 (Q-W)	(1) Type (e.g., buy, sell, redemption)	(2) Date mm/dd/yy	(3) Value Code 2 (J-P)	(4) Gain Code 1 (A-H)	(5) Identity of buyer/seller (if private transaction)
69. - Acadia Pharmaceuticals C.S.					Sold	07/20/15	J	D	
70. - Agios C.S.					Buy	12/07/15	J		
71. - Amgen C.S.									
72. - Arch Coal C.S.					Sold	02/06/15	J		
73. - Bank of America C.S.									
74. - Barrick Gold Corp. C.S.									
75. - Berkshire Hathaway (B) C.S.									
76. - Biogen C.S.					Buy	10/13/15	L		
77. - BP ADR									
78. - Celgene C.S.									
79. - Chevron C.S.									
80. - Conoco Phillips C.S.									
81. - Encana Corp C.S.									
82. - Exxon C.S.									
83. - Freeport McMoran C.S.									
84. - General Electric Co. C.S.									
85. - Gilead Sciences Inc. C.S.									

1. Income Gain Codes: (See Columns B1 and D4)	A = \$1,000 or less F = \$50,001 - \$100,000	B = \$1,001 - \$2,500 G = \$100,001 - \$1,000,000	C = \$2,501 - \$5,000 H1 = \$1,000,001 - \$5,000,000	D = \$5,001 - \$15,000 H2 = More than \$5,000,000	E = \$15,001 - \$50,000
2. Value Codes (See Columns C1 and D3)	J = \$15,000 or less N = \$250,001 - \$500,000 P3 = \$25,000,001 - \$50,000,000	K = \$15,001 - \$50,000 O = \$500,001 - \$1,000,000	L = \$50,001 - \$100,000 P1 = \$1,000,001 - \$5,000,000 P4 = More than \$5,000,000	M = \$100,001 - \$250,000 P2 = \$5,000,001 - \$25,000,000	
3. Value Method Codes (See Column C2)	Q = Appraisal U = Book Value	R = Cost (Real Estate Only) V = Other	S = Assessment W = Estimated	T = Cash Market	

FINANCIAL DISCLOSURE REPORT

Page 9 of 20

Name of Person Reporting

Ray, J. Thomas

Date of Report

08/04/2016

VII. INVESTMENTS and TRUSTS -- income, value, transactions (Includes those of spouse and dependent children; see pp. 34-60 of filing instructions.)

☐ NONE (No reportable income, assets, or transactions.)

A. Description of Assets (including trust assets) Place "(X)" after each asset exempt from prior disclosure	B. Income during reporting period		C. Gross value at end of reporting period		D. Transactions during reporting period				
	(1) Amount Code 1 (A-H)	(2) Type (e.g., div., rent, or int.)	(1) Value Code 2 (J-P)	(2) Value Method Code 3 (Q-W)	(1) Type (e.g., buy, sell, redemption)	(2) Date mm/dd/yy	(3) Value Code 2 (J-P)	(4) Gain Code 1 (A-H)	(5) Identity of buyer/seller (if private transaction)
86. - J.P. Morgan C.S.									
87. - Johnson & Johnson C.S.									
88. - Kinder Morgan Inc. C.S.									
89. - Merck & Co. Inc. C.S.									
90. - Medivation C.S.									
91. - Pfizer Inc. C.S.									
92. - Phillips 66 C.S.									
93. - Rio Tinto ADR					Sold	04/28/15	K	A	
94. - Roche Hldg ADR									
95. - Sanofi Aventis C.S.									
96. - Schlumberger C.S.									
97. - Seattle Genetics Inc. C.S.					Sold	05/28/15	K	C	
98. - Stemline Therapeutics C.S.									
99. - Stryker C.S.					Sold	08/07/15	K	E	
100. - Total ADR					Sold	04/22/15	K	C	
101. - Transocean Inc. C.S.									
102. - Wells Fargo & Co. C.S.									

1. Income Gain Codes: (See Columns B1 and D4)	A = \$1,000 or less F = \$50,001 - \$100,000	B = \$1,001 - \$2,500 G = \$100,001 - \$1,000,000	C = \$2,501 - \$5,000 H1 = \$1,000,001 - \$5,000,000	D = \$5,001 - \$15,000 H2 = More than \$5,000,000	E = \$15,001 - \$50,000
2. Value Codes (See Columns C1 and D3)	J = \$15,000 or less N = \$250,001 - \$500,000 P3 = \$25,000,001 - \$50,000,000	K = \$15,001 - \$50,000 O = \$500,001 - \$1,000,000	L = \$50,001 - \$100,000 P1 = \$1,000,001 - \$5,000,000 P4 = More than \$50,000,000	M = \$100,001 - \$250,000 P2 = \$5,000,001 - \$25,000,000	
3. Value Method Codes (See Column C2)	Q = Appraisal U = Book Value	R = Cost (Real Estate Only) V = Other	S = Assessment W = Estimated	T = Cash Market	

FINANCIAL DISCLOSURE REPORT

Page 10 of 20

Name of Person Reporting

Ray, J. Thomas

Date of Report

08/04/2016

VII. INVESTMENTS and TRUSTS -- income, value, transactions (Includes those of spouse and dependent children; see pp. 34-60 of filing instructions.)

☐ NONE (No reportable income, assets, or transactions.)

A. Description of Assets (including trust assets) Place "(X)" after each asset exempt from prior disclosure	B. Income during reporting period		C. Gross value at end of reporting period		D. Transactions during reporting period				
	(1) Amount Code 1 (A-H)	(2) Type (e.g., div., rent, or int.)	(1) Value Code 2 (J-P)	(2) Value Method Code 3 (Q-W)	(1) Type (e.g., buy, sell, redemption)	(2) Date mm/dd/yy	(3) Value Code 2 (J-P)	(4) Gain Code 1 (A-H)	(5) Identity of buyer/seller (if private transaction)

103.									
104. IRA #1	C	Dividend	N	T					
105. - Agios C.S.					Buy	12/07/15	J		
106. - Amgen Inc. C.S.									
107. - Bank of America C.S.									
108. - Barrick Gold Corp. C.S.									
109. - Berkshire Hathaway (B) C.S.									
110. - BP PLC C.S.									
111. - Celgene C.S.									
112. - Conoco C.S.									
113. - Dow Chemical Co C.S.									
114. - Exxon Mobil C.S.									
115. - Freeport McMoran									
116. - Gilead Sciences Inc. C.S.									
117. - Johnson & Johnson C.S.									
118. - J.P. Morgan Chase C.S.									
119. - Merck C.S.									

1. Income Gain Codes: (See Columns B1 and D4)	A ~\$1,000 or less F ~\$50,001 - \$100,000	B ~\$1,001 - \$2,500 G ~\$100,001 - \$1,000,000	C ~\$2,501 - \$5,000 H1 ~\$1,000,001 - \$5,000,000	D ~\$5,001 - \$15,000 H2 ~More than \$5,000,000	E ~\$15,001 - \$50,000
2. Value Codes (See Columns C1 and D3)	J ~\$15,000 or less N ~\$250,001 - \$500,000 P3 ~\$25,000,001 - \$50,000,000	K ~\$15,001 - \$50,000 O ~\$500,001 - \$1,000,000	L ~\$50,001 - \$100,000 P1 ~\$1,000,001 - \$5,000,000 P4 ~More than \$50,000,000	M ~\$100,001 - \$250,000 P2 ~\$5,000,001 - \$25,000,000	
3. Value Method Codes (See Column C2)	Q = Appraisal U = Book Value	R = Cost (Real Estate Only) V = Other	S = Assessment W = Estimated	T = Cash Market	

FINANCIAL DISCLOSURE REPORT

Page 11 of 20

Name of Person Reporting

Ray, J. Thomas

Date of Report

08/04/2016

VII. INVESTMENTS and TRUSTS – income, value, transactions (Includes those of spouse and dependent children; see pp. 34-60 of filing instructions.)

☐ NONE (No reportable income, assets, or transactions.)

A. Description of Assets (including trust assets) Place "(X)" after each asset exempt from prior disclosure	B. Income during reporting period		C. Gross value at end of reporting period		D. Transactions during reporting period				
	(1) Amount Code 1 (A-H)	(2) Type (e.g., div., rent, or int.)	(1) Value Code 2 (J-P)	(2) Value Method Code 3 (Q-W)	(1) Type (e.g., buy, sell, redemption)	(2) Date mm/dd/yy	(3) Value Code 2 (J-P)	(4) Gain Code 1 (A-H)	(5) Identity of buyer/seller (if private transaction)
120. - Phillips 66 C.S.									
121. - Pfizer C.S.									
122. - Seattle Genetics Inc. C.S.					Sold	06/01/15	J	B	
123. - Stemline Therapeutics C.S.					Buy	12/16/15	J		
124. - Transocean Inc. C.S.									
125. - Whiting Petroleum					Buy	12/16/15	J		
126. - Money Market (Cash Equivalents)									
127.									
128. Inherited IRA (X)	B	Dividend	M	T					
129. - AbbVie Inc. C.S. (X)									
130. - Agios C.S. (X)									
131. - Alexion C.S. (X)									
132. - Berkshire Hathaway C.S. (X)									
133. - Biogen Inc. C.S. (X)									
134. - Celgene C.S. (X)									
135. - Chevron C.S. (X)									
136. - Coca Cola C.S. (X)									

1. Income Gain Codes: (See Columns B1 and D4)	A = \$1,000 or less F = \$50,001 - \$100,000	B = \$1,001 - \$2,500 G = \$100,001 - \$1,000,000	C = \$2,501 - \$5,000 H1 = \$1,000,001 - \$5,000,000	D = \$5,001 - \$15,000 H2 = More than \$5,000,000	E = \$15,001 - \$50,000
2. Value Codes (See Columns C1 and D3)	J = \$15,000 or less N = \$250,001 - \$500,000 P3 = \$25,000,001 - \$50,000,000	K = \$15,001 - \$50,000 O = \$500,001 - \$1,000,000	L = \$50,001 - \$100,000 P1 = \$1,000,001 - \$5,000,000 P4 = More than \$50,000,000	M = \$100,001 - \$250,000 P2 = \$5,000,001 - \$25,000,000	
3. Value Method Codes (See Column C2)	Q = Appraisal U = Book Value	R = Cost (Real Estate Only) V = Other	S = Assessment W = Estimated	T = Cash Market	

FINANCIAL DISCLOSURE REPORT

Page 12 of 20

Name of Person Reporting

Ray, J. Thomas

Date of Report

08/04/2016

VII. INVESTMENTS and TRUSTS -- income, value, transactions (Includes those of spouse and dependent children; see pp. 34-60 of filing instructions.)
☐ NONE (No reportable income, assets, or transactions.)

A. Description of Assets (including trust assets) Place "(X)" after each asset exempt from prior disclosure	B. Income during reporting period		C. Gross value at end of reporting period		D. Transactions during reporting period				
	(1) Amount Code 1 (A-H)	(2) Type (e.g., div., rent, or int.)	(1) Value Code 2 (J-P)	(2) Value Method Code 3 (Q-W)	(1) Type (e.g., buy, sell, redemption)	(2) Date mm/dd/yy	(3) Value Code 2 (J-P)	(4) Gain Code 1 (A-H)	(5) Identity of buyer/seller (if private transaction)
137. - Conoco Phillips C.S. (X)									
138. - Diageo PLC ADR (X)									
139. - Gilead Science Inc. C.S. (X)									
140. - Honeywell Inc. C.S. (X)									
141. - Johnson & Johnson C.S. (X)									
142. - Medivation Inc. C.S. (X)									
143. - Merck C.S. (X)									
144. - Mondelez C.S. (X)									
145. - Occidental C.S. (X)									
146. - Pfizer C.S. (X)									
147. - Proctor & Gamble C.S. (X)									
148. - Time Warner Inc. C.S. (X)									
149. - Wells Fargo & Co. C.S. (X)									
150. - Whiting Petroleum C.S. (X)									
151. - Dodge & Cox Intl. Stock M.F. (X)									
152. - Matthews Pacific Tiger M.F. (X)									
153. - Pimco Commodities Plus M.F. (X)									

1. Income Gain Codes: (See Columns B1 and D4)	A = \$1,000 or less F = \$50,001 - \$100,000	B = \$1,001 - \$2,500 G = \$100,001 - \$1,000,000	C = \$2,501 - \$5,000 H1 = \$1,000,001 - \$5,000,000	D = \$5,001 - \$15,000 H2 = More than \$5,000,000	E = \$15,001 - \$50,000
2. Value Codes (See Columns C1 and D3)	J = \$15,000 or less N = \$250,001 - \$500,000 P3 = \$25,000,001 - \$50,000,000	K = \$15,001 - \$50,000 O = \$500,001 - \$1,000,000	L = \$50,001 - \$100,000 P1 = \$1,000,001 - \$5,000,000 P4 = More than \$50,000,000	M = \$100,001 - \$250,000 P2 = \$5,000,001 - \$25,000,000	
3. Value Method Codes (See Column C2)	Q = Appraisal U = Book Value	R = Cost (Real Estate Only) V = Other	S = Assessment W = Estimated	T = Cash Market	

FINANCIAL DISCLOSURE REPORT

Page 13 of 20

Name of Person Reporting

Ray, J. Thomas

Date of Report

08/04/2016

VII. INVESTMENTS and TRUSTS -- income, value, transactions (Includes those of spouse and dependent children; see pp. 34-60 of filing instructions.)

☐ NONE (No reportable income, assets, or transactions.)

A. Description of Assets (including trust assets) Place "(X)" after each asset exempt from prior disclosure	B. Income during reporting period		C. Gross value at end of reporting period		D. Transactions during reporting period				
	(1) Amount Code 1 (A-H)	(2) Type (e.g., div., rent, or int.)	(1) Value Code 2 (J-P)	(2) Value Method Code 3 (Q-W)	(1) Type (e.g., buy, sell, redemption)	(2) Date mm/dd/yy	(3) Value Code 2 (J-P)	(4) Gain Code 1 (A-H)	(5) Identity of buyer/seller (if private transaction)
154. - Preimcap Odyssey Stock M.F. (X)									
155. - T. Rowe Price Overseas M.F. (X)									
156. - Money Market (Cash Equivalents) (X)									
157.									
158. IRA #2	C	Dividend	N	T					
159. - Amgen Inc. C.S.									
160. - Bank of America C.S.									
161. - Barrick Gold Corp. C.S.									
162. - Berkshire Hathaway (B) C.S.									
163. - Celgene C.S.									
164. - Conoco C.S.									
165. - Exxon C.S.									
166. - Freeport McMoran Inc. C.S.					Sold	12/08/15	J		
167. - Gilead Sciences Inc. C.S.									
168. - Johnson & Johnson C.S.									
169. - Merck C.S.									
170. - Pfizer Inc. C.S.									

1. Income Gain Codes: (See Columns B1 and D4)	A = \$1,000 or less F = \$50,001 - \$100,000	B = \$1,001 - \$2,500 G = \$100,001 - \$1,000,000	C = \$2,501 - \$5,000 H1 = \$1,000,001 - \$5,000,000	D = \$5,001 - \$15,000 H2 = More than \$5,000,000	E = \$15,001 - \$50,000
2. Value Codes (See Columns C1 and D3)	J = \$15,000 or less N = \$250,001 - \$500,000 P3 = \$25,000,001 - \$50,000,000	K = \$15,001 - \$50,000 O = \$500,001 - \$1,000,000	L = \$50,001 - \$100,000 P1 = \$1,000,001 - \$5,000,000 P4 = More than \$50,000,000	M = \$100,001 - \$250,000 P2 = \$5,000,001 - \$25,000,000	
3. Value Method Codes (See Column C2)	Q = Appraisal U = Book Value	R = Cost (Real Estate Only) V = Other	S = Assessment W = Estimated	T = Cash Market	

FINANCIAL DISCLOSURE REPORT

Page 14 of 20

Name of Person Reporting

Ray, J. Thomas

Date of Report

08/04/2016

VII. INVESTMENTS and TRUSTS -- income, value, transactions (Includes those of spouse and dependent children; see pp. 34-60 of filing instructions.)

☐ NONE (No reportable income, assets, or transactions.)

A. Description of Assets (including trust assets) Place "(X)" after each asset exempt from prior disclosure	B. Income during reporting period		C. Gross value at end of reporting period		D. Transactions during reporting period				
	(1) Amount Code 1 (A-H)	(2) Type (e.g., div., rent, or int.)	(1) Value Code 2 (J-P)	(2) Value Method Code 3 (Q-W)	(1) Type (e.g., buy, sell, redemption)	(2) Date mm/dd/yy	(3) Value Code 2 (J-P)	(4) Gain Code 1 (A-H)	(5) Identity of buyer/seller (if private transaction)
171. - Seattle Genetics Inc. C.S.					Sold	06/01/15	J	B	
172. - Transocean Inc. C.S.					Sold	12/08/15	J		
173. - Money Market (Cash Equivalents)									
174.									
175. Trust #1	C	Dividend	N	T					
176. - Amgen Inc. C.S.									
177. - Bank of America C.S.									
178. - Barrick Gold Corp. C.S.									
179. - Berkshire Hathaway C.S.					Buy	09/01/15	J		
180. - Biogen C.S.					Buy	10/13/15	K		
181. - Celgene C.S.									
182. - Chevron C.S.					Buy	08/21/15	K		
183. - Conoco Phillips C.S.									
184. - Gilead Sciences Inc. C.S.									
185. - Johnson & Johnson C.S.									
186. - Pfizer C.S.									
187. - Phillips 66 C.S.									

1. Income Gain Codes: (See Columns B1 and D4)	A - \$1,000 or less F - \$50,001 - \$100,000	B - \$1,001 - \$2,500 G - \$100,001 - \$1,000,000	C - \$2,501 - \$5,000 H1 - \$1,000,001 - \$5,000,000	D - \$5,001 - \$15,000 H2 - More than \$5,000,000	E - \$15,001 - \$50,000
2. Value Codes (See Columns C1 and D3)	J - \$15,000 or less N - \$250,001 - \$500,000 P3 - \$25,000,001 - \$50,000,000	K - \$15,001 - \$50,000 O - \$500,001 - \$1,000,000	L - \$50,001 - \$100,000 P1 - \$1,000,001 - \$5,000,000 P4 - More than \$5,000,000	M - \$100,001 - \$250,000 P2 - \$5,000,001 - \$25,000,000	
3. Value Method Codes (See Column C2)	Q - Appraisal U - Book Value	R - Cost (Real Estate Only) V - Other	S - Assessment W - Estimated	T - Cash Market	

FINANCIAL DISCLOSURE REPORT

Page 15 of 20

Name of Person Reporting

Ray, J. Thomas

Date of Report

08/04/2016

VII. INVESTMENTS and TRUSTS -- income, value, transactions (Includes those of spouse and dependent children; see pp. 34-60 of filing instructions.)

☐ NONE (No reportable income, assets, or transactions.)

A. Description of Assets (including trust assets) Place "(X)" after each asset exempt from prior disclosure	B. Income during reporting period		C. Gross value at end of reporting period		D. Transactions during reporting period				
	(1) Amount Code 1 (A-H)	(2) Type (e.g., div., rent, or int.)	(1) Value Code 2 (J-P)	(2) Value Method Code 3 (Q-W)	(1) Type (e.g., buy, sell, redemption)	(2) Date mm/dd/yy	(3) Value Code 2 (J-P)	(4) Gain Code 1 (A-H)	(5) Identity of buyer/seller (if private transaction)
188. - Transocean Inc. C.S.									
189. - Money Market (Cash Equivalents)									
190.									
191. Trust #2	E	Dividend	P1	T					
192. - Acadia C.S.					Buy	10/21/15	J		
193. - Agios C.S.					Buy	12/07/15	K		
194. - Alexion C.S.					Buy	05/06/15	J		
195. - Amgen Inc. C.S.									
196. - Apache Corp. C.S.									
197. - Bank of America C.S.									
198. - Barrick Gold Corp. C.S.									
199. - Berkshire Hathaway (B) C.S.									
200. - Biogen C.S.					Buy	10/13/15	L		
201. - BP ADR (F)									
202. - Celgene C.S.									
203. - Chevron C.S.									
204. - Dow Chemical Co. C.S.									

1. Income Gain Codes: (See Columns B1 and D4)	A = \$1,000 or less F = \$50,001 - \$100,000	B = \$1,001 - \$2,500 G = \$100,001 - \$1,000,000	C = \$2,501 - \$5,000 H1 = \$1,000,001 - \$5,000,000	D = \$5,001 - \$15,000 H2 = More than \$5,000,000	E = \$15,001 - \$50,000
2. Value Codes (See Columns C1 and D3)	J = \$15,000 or less N = \$250,001 - \$500,000 P3 = \$25,000,001 - \$50,000,000	K = \$15,001 - \$50,000 O = \$500,001 - \$1,000,000	L = \$50,001 - \$100,000 P1 = \$1,000,001 - \$5,000,000 P4 = More than \$5,000,000	M = \$100,001 - \$250,000 P2 = \$5,000,001 - \$25,000,000	
3. Value Method Codes (See Column C2)	Q = Appraisal U = Book Value	R = Cost (Real Estate Only) V = Other	S = Assessment W = Estimated	T = Cash Market	

FINANCIAL DISCLOSURE REPORT

Page 16 of 20

Name of Person Reporting

Ray, J. Thomas

Date of Report

08/04/2016

VII. INVESTMENTS and TRUSTS – income, value, transactions (Includes those of spouse and dependent children; see pp. 34-60 of filing instructions.)

☐ NONE (No reportable income, assets, or transactions.)

A. Description of Assets (including trust assets) Place "(X)" after each asset exempt from prior disclosure	B. Income during reporting period		C. Gross value at end of reporting period		D. Transactions during reporting period				
	(1) Amount Code 1 (A-H)	(2) Type (e.g., div., rent, or int.)	(1) Value Code 2 (J-P)	(2) Value Method Code 3 (Q-W)	(1) Type (e.g., buy, sell, redemption)	(2) Date mm/dd/yy	(3) Value Code 2 (J-P)	(4) Gain Code 1 (A-H)	(5) Identity of buyer/seller (if private transaction)
205. - DuPont Co. C.S.					Sold	10/13/15	J	C	
206. - Exxon C.S.									
207. - Freeport McMoran C.S.									
208. - General Electric C.S.									
209. - Gilead Sciences Inc. C.S.									
210. - Johnson & Johnson C.S.									
211. - Kinder Morgan C.S.									
212. - Medivation C.S.									
213. - Merck & Co. C.S.									
214. - Pfizer C.S.									
215. - Pharmacyclics C.S.					Sold	01/26/15	K		
216. - Phillips 66 C.S.									
217. - Phillips 66 Partners									
218. - Rio Tinto ADR (F)					Sold	04/28/15	K	A	
219. - Sanofi Aventis C.S.									
220. - Seattle Genetics C.S.					Sold	05/28/15	K	C	
221. - Stemline Therapeutics C.S.									

1. Income Gain Codes: (See Columns B1 and D4)	A = \$1,000 or less F = \$50,001 - \$100,000	B = \$1,001 - \$2,500 G = \$100,001 - \$1,000,000	C = \$2,501 - \$5,000 H1 = \$1,000,001 - \$5,000,000	D = \$5,001 - \$15,000 H2 = More than \$5,000,000	E = \$15,001 - \$50,000
2. Value Codes (See Columns C1 and D3)	J = \$15,000 or less N = \$250,001 - \$500,000 P3 = \$25,000,001 - \$50,000,000	K = \$15,001 - \$50,000 O = \$500,001 - \$1,000,000	L = \$50,001 - \$100,000 P1 = \$1,000,001 - \$5,000,000 P4 = More than \$5,000,000	M = \$100,001 - \$250,000 P2 = \$5,000,001 - \$25,000,000	
3. Value Method Codes (See Column C2)	Q = Appraisal U = Book Value	R = Cost (Real Estate Only) V = Other	S = Assessment W = Estimated	T = Cash Market	

FINANCIAL DISCLOSURE REPORT

Page 17 of 20

Name of Person Reporting

Ray, J. Thomas

Date of Report

08/04/2016

VII. INVESTMENTS and TRUSTS – income, value, transactions (Includes those of spouse and dependent children; see pp. 34-60 of filing instructions.)

☐ NONE (No reportable income, assets, or transactions.)

A. Description of Assets (including trust assets) Place "(X)" after each asset exempt from prior disclosure	B. Income during reporting period		C. Gross value at end of reporting period		D. Transactions during reporting period				
	(1) Amount Code 1 (A-H)	(2) Type (e.g., div., rent, or int.)	(1) Value Code 2 (J-P)	(2) Value Method Code 3 (Q-W)	(1) Type (e.g., buy, sell, redemption)	(2) Date mm/dd/yy	(3) Value Code 2 (J-P)	(4) Gain Code 1 (A-H)	(5) Identity of buyer/seller (if private transaction)
222. - Stryker C.S.									
223. - Transocean Inc. C.S.									
224. - Vale C.S.					Sold	09/21/15	J		
225. - Wells Fargo C.S.									
226. - Whiting Petroleum C.S.					Buy	12/08/15	K		
227. - Money Market (Cash Equivalents)									
228.									
229. Trust #3	B	Dividend	M	T					
230. - AbbVie C.S.					Buy	03/09/15	J		
231. - Agios C.S.					Buy	03/25/15	J		
232. - Berkshire Hathaway (B) C.S.									
233. - Celgene C.S.					Buy	04/30/15	J		
234. - Conoco Phillips C.S.									
235. - Dow Chemical Co. C.S.									
236. - Encana Corp. C.S.									
237. - Exxon C.S.					Buy	03/05/15	J		
238. - Freeport McMoran Inc. C.S.									

1. Income Gain Codes:	A = \$1,000 or less	B = \$1,001 - \$2,500	C = \$2,501 - \$5,000	D = \$5,001 - \$15,000	E = \$15,001 - \$50,000
(See Columns B1 and D4)	F = \$50,001 - \$100,000	G = \$100,001 - \$1,000,000	H1 = \$1,000,001 - \$5,000,000	H2 = More than \$5,000,000	
2. Value Codes	J = \$15,000 or less	K = \$15,001 - \$50,000	L = \$50,001 - \$100,000	M = \$100,001 - \$250,000	
(See Columns C1 and D3)	N = \$250,001 - \$500,000	O = \$500,001 - \$1,000,000	P1 = \$1,000,001 - \$5,000,000	P2 = \$5,000,001 - \$25,000,000	
	P3 = \$25,000,001 - \$50,000,000		P4 = More than \$50,000,000		
3. Value Method Codes	Q = Appraisal	R = Cost (Real Estate Only)	S = Assessment	T = Cash Market	
(See Column C2)	U = Book Value	V = Other	W = Estimated		

FINANCIAL DISCLOSURE REPORT

Page 18 of 20

Name of Person Reporting

Ray, J. Thomas

Date of Report

08/04/2016

VII. INVESTMENTS and TRUSTS – income, value, transactions (Includes those of spouse and dependent children; see pp. 34-60 of filing instructions.)

☐ NONE (No reportable income, assets, or transactions.)

A. Description of Assets (including trust assets) Place "(X)" after each asset exempt from prior disclosure	B. Income during reporting period		C. Gross value at end of reporting period		D. Transactions during reporting period				
	(1) Amount Code I (A-H)	(2) Type (e.g., div., rent, or int.)	(1) Value Code 2 (J-P)	(2) Value Method Code 3 (Q-W)	(1) Type (e.g., buy, sell, redemption)	(2) Date mm/dd/yy	(3) Value Code 2 (J-P)	(4) Gain Code 1 (A-H)	(5) Identity of buyer/seller (if private transaction)

239. - Gilead Sciences, Inc. C.S.									
240. - Merck C.S.									
241. - Phillips 66 C.S.					Buy	01/14/15	J		
242. - Roche C.S.					Buy	02/12/15	J		
243. - Sanofi C.S.					Buy	01/05/15	J		
244. - Schlumberger C.S.									
245. - Whiting Petroleum C.S.					Buy	12/18/15	J		
246. - Money Market (Cash Equivalents)									
247. Life Insurance -Flexible Premium Adjustable Life Ins. Policy	C	Interest	M	T					

1. Income Gain Codes: (See Columns B1 and D4)	A = \$1,000 or less F = \$50,001 - \$100,000	B = \$1,001 - \$2,500 G = \$100,001 - \$1,000,000	C = \$2,501 - \$5,000 H1 = \$1,000,001 - \$5,000,000	D = \$5,001 - \$15,000 H2 = More than \$5,000,000	E = \$15,001 - \$50,000
2. Value Codes (See Columns C1 and D3)	J = \$15,000 or less N = \$250,001 - \$500,000 P3 = \$25,000,001 - \$50,000,000	K = \$15,001 - \$50,000 O = \$500,001 - \$1,000,000	L = \$50,001 - \$100,000 P1 = \$1,000,001 - \$5,000,000 P4 = More than \$50,000,000	M = \$100,001 - \$250,000 P2 = \$5,000,001 - \$25,000,000	
3. Value Method Codes (See Column C2)	Q = Appraisal U = Book Value	R = Cost (Real Estate Only) V = Other	S = Assessment W = Estimated	T = Cash Market	

FINANCIAL DISCLOSURE REPORT

Page 19 of 20

Name of Person Reporting	Date of Report
Ray, J. Thomas	08/04/2016

VIII. ADDITIONAL INFORMATION OR EXPLANATIONS. *(Indicate part of report.)*

Line 128: Assets held in inherited IRA were transferred and received on February 17, 2015.

FINANCIAL DISCLOSURE REPORT

Page 20 of 20

Name of Person Reporting

Ray, J. Thomas

Date of Report

08/04/2016

IX. CERTIFICATION.

I certify that all information given above (including information pertaining to my spouse and minor or dependent children, if any) is accurate, true, and complete to the best of my knowledge and belief, and that any information not reported was withheld because it met applicable statutory provisions permitting non-disclosure.

I further certify that earned income from outside employment and honoraria and the acceptance of gifts which have been reported are in compliance with the provisions of 5 U.S.C. app. § 501 et. seq., 5 U.S.C. § 7353, and Judicial Conference regulations.

Signature: **s/ J. Thomas Ray**

NOTE: ANY INDIVIDUAL WHO KNOWINGLY AND WILLFULLY FALSIFIES OR FAILS TO FILE THIS REPORT MAY BE SUBJECT TO CIVIL AND CRIMINAL SANCTIONS (5 U.S.C. app. § 104)

Committee on Financial Disclosure
Administrative Office of the United States Courts
Suite 2-301
One Columbus Circle, N.E.
Washington, D.C. 20544